Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Rhythm Pharmaceuticals Q1 2026 Earnings Call - Acquired HO Launch Accelerates with 150+ Start Forms in Six Weeks
Rhythm Pharmaceuticals delivered a strong Q1 2026, driven by steady growth in its ultra-rare Bardet-Biedl syndrome (BBS) base business and the rapid commercial launch of IMCIVREE for acquired hypothal...
- U.S. net revenues reached $60.1 million in Q1 2026, up 5% sequentially, with $36.9 million from the U.S. and $23.2 million internationally.
- IMCIVREE for acquired hypothalamic obesity (HO) launched in the U.S. on March 19, capturing 150+ start forms in six weeks, with ~40 from clinical trial conversions and 80% from new prescribers.
- HO launch pace outpaces Bardet-Biedl syndrome (BBS); early payer approval rates improved due to prior BBS-based education, though specific HO policies expected in 3–9 months.
- +12 more takeaways
Embecta Corp Q2 FY2026 Earnings Call - U.S. Pen Needle Share Loss Drives Guidance Cut and Owen Mumford Acquisition
Embecta delivered a disappointing second quarter of fiscal 2026, with consolidated revenues falling 14.4% year-over-year as U.S. pen needle sales collapsed under competitive share loss and broader mar...
- U.S. Revenue Collapse: U.S. revenue fell 29.4% year-over-year, driven primarily by competitive share loss at a single major customer and broader market softness in insulin pen prescriptions.
- Guidance Cut: Full-year FY2026 revenue guidance is lowered to $1.015 billion–$1.035 billion, reflecting a ~$75 million reduction in organic revenue expectations compared to prior low-end guidance.
- Pen Needle Headwinds: Pen needles, which make up ~70% of the guidance reduction, suffered from ~$25 million in share loss and ~$20 million in market volume softness, exacerbated by patients shifting to lower-cost channels.
- +7 more takeaways
DuPont Q1 2026 Earnings Call - Strong Q1 Results and Raised Full-Year Guidance Driven by Healthcare, Aerospace, and Productivity Gains
DuPont delivered a strong start to 2026, beating guidance with 2% organic sales growth, 130 basis points of pro forma margin expansion, and double-digit adjusted EPS growth. The company closed the $1....
- DuPont reported Q1 2026 net sales of $1.7 billion, up 4% year-over-year, driven by 2% organic growth and a 2% currency benefit. Results exceeded prior guidance.
- Operating EBITDA surged 15% to $414 million, with pro forma margins expanding 130 basis points to 24.6%, reflecting strong operational execution and favorable mix.
- Adjusted EPS reached $0.55 on a reported basis (up 53% YoY) and $0.55 on a pro forma basis (up 20% YoY), beating consensus expectations.
- +9 more takeaways
JELD-WEN Q1 2026 Earnings Call - Service Improvements Offset Volume Declines, Raised Revenue Guidance
JELD-WEN Holdings reported a challenging first quarter, with net revenue falling 7% year-over-year to $722 million and adjusted EBITDA collapsing 72% to $6 million. The decline was driven by a steep d...
- Revenue fell 7% year-over-year to $722 million, driven by a 10% core revenue decline as lower volumes overwhelmed slight pricing gains.
- Adjusted EBITDA collapsed 72% to just $6 million, with a 0.9% margin, as $22 million in volume headwinds and $21 million in price-cost inflation offset $22 million in productivity gains.
- Management raised full-year 2026 revenue guidance to $3.05-$3.2 billion, up from $2.95-$3.1 billion, citing improved service levels and better-than-expected April sales.
- +7 more takeaways
Eve Holding Q1 2026 Earnings Call - Engineering Prototype Flight Tests Validate Path to 2028 Certification
Eve Holding delivered a strong operational quarter, logging 59 flights and validating 130 performance points with its engineering prototype. The company is on track to begin transition flights in the ...
- Eve completed 59 flights and logged nearly two and a half hours in the air with its engineering prototype, validating 130 distinct performance points and reaching 215 feet in altitude and 30 knots forward speed.
- The company is preparing to initiate transition flights in the second quarter, moving from hover mode to partial transition and eventually full wing-borne flight above 85 knots.
- Eve remains on track for certification prototype first flights in the second half of 2027 and a targeted entry to service in 2028, contingent on a 12-month certification flight test campaign.
- +7 more takeaways
Shoals Technologies Group Q1 2026 Earnings Call - Record Backlog and Raised Guidance Signal Solar Demand Resilience
Shoals Technologies Group reported a strong start to 2026, with Q1 revenue of $140.6 million, up 75% year-over-year, driven by robust demand in the U.S. utility-scale solar market. The company achieve...
- Revenue surged 75% year-over-year to $140.6 million, beating guidance and reflecting strong demand in the U.S. utility-scale solar market.
- Record backlog and awarded orders (BLAO) reached $758 million, up 18% year-over-year, with $628 million scheduled for delivery through Q1 2027.
- Adjusted EBITDA grew 56% year-over-year to $21.1 million, landing at the high end of guidance and signaling strong operating leverage.
- +7 more takeaways
Ocular Therapeutix Q1 2026 Earnings Call - AXPAXLI Demonstrates Unprecedented Superiority in Wet AMD
Ocular Therapeutix delivered a transformative update on AXPAXLI (SOL-1), marking the first time a novel investigational therapy has statistically and clinically surpassed an approved anti-VEGF agent i...
- AXPAXLI (SOL-1) achieved statistical superiority over aflibercept in Phase III wet AMD with a p-value of 0.0006, marking the first time a novel investigational therapy has beaten an approved anti-VEGF in this indication.
- Unmatched durability: Two-thirds of patients maintained vision with a single injection for an entire year, while 66% sustained vision through 12 months in a highly treatment-naive, high-risk population.
- Superior disease control: AXPAXLI delayed time to fluid volume increases by 5-6 months compared to aflibercept, with a 6-month delay in reaching clinically meaningful rescue thresholds.
- +7 more takeaways
Labcorp Holdings Q1 2026 Earnings Call - Specialty Testing Momentum and Margin Expansion Drive Upside
Labcorp delivered a strong start to 2026, with Q1 revenue rising 5.8% to $3.5 billion and adjusted EPS climbing 10.6% to $4.25. The growth was broadly based, with Diagnostics Laboratories up 5% and Bi...
- Q1 2026 revenue reached $3.5 billion, up 5.8% year-over-year, with adjusted EPS growing 10.6% to $4.25.
- Organic revenue growth was 3.1%, driven by strong performance in both Diagnostics and Biopharma Laboratory Services segments.
- Diagnostics Laboratories revenue grew 5% to $2.8 billion, with 2.9% organic growth and a 2.6% price mix increase.
- +7 more takeaways
EVgo Q1 2026 Earnings Call - Record $110M Revenue and DOE Loan Amendment Fuel Aggressive Buildout
EVgo delivered record Q1 2026 revenue of $110 million, driven by a 45% year-over-year surge in its operating network and new dedicated AV hub contracts. The company added 200 new stalls, bringing tota...
- Record Q1 2026 revenue of $110 million, up 45% year-over-year, driven by network expansion and new AV hub contracts.
- Total stalls in operation reached 5,280, with 200 new stalls added in Q1, including 100 new public EVgo-owned stalls.
- Public network throughput hit 91 GWh in Q1, a 10% year-over-year increase, though daily per-stall throughput dipped 3.5% due to seasonal weather and new stall ramp-up.
- +9 more takeaways
Dorman Products Q1 2026 Earnings Call - Tariff Costs Weigh on Margins as Management Reaffirms Full-Year Guidance
Dorman Products reported a solid but margin-constrained first quarter, with net sales rising 4% to $529 million and adjusted EPS of $1.57, down 22% year-over-year. The decline was driven by the highes...
- Net sales rose 4% year-over-year to $529 million, driven by pricing actions that offset lower volumes against a strong prior-year quarter.
- Adjusted diluted EPS came in at $1.57, down 22% year-over-year, primarily due to elevated tariff-related cost of goods sold recognized via FIFO.
- Adjusted operating margin contracted to 12.1%, a 490 basis point decline, reflecting the peak tariff expense Dorman expects to recognize in 2026.
- +7 more takeaways